Iovance Biotherapeutics Interest Expense 2011-2026 | IOVA

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Iovance Biotherapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	-	-	-	-	200 K	-5.66 K	445 K	1.92 M	152 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.92 M	-5.66 K	543 K

Quarterly Interest Expense Iovance Biotherapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	221 K	164 K	126 K	-	8 K	73 K	-	-	-4.19 K	-	-	-	-	104 K	342 K	-	127 K	111 K	88.5 K	-	31.6 K	-399 K	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
342 K	-399 K	76.4 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
BioNTech SE BNTX	14.2 M	-	-	$ 27.2 B	Germany
INmune Bio INMB	2.28 M	$ 1.52	-1.3 %	$ 37.6 M	USA
Exelixis EXEL	-198 K	$ 48.7	9.64 %	$ 13.2 B	USA
ACADIA Pharmaceuticals ACAD	1.82 M	$ 21.48	-3.89 %	$ 3.56 B	USA
Fortress Biotech FBIO	17.6 M	-	-	$ 71.1 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 3.15	1.19 %	$ 655 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	-	-	$ 5.51 M	Israel
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 24.17	3.2 %	$ 3.08 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
CRISPR Therapeutics AG CRSP	86.6 M	$ 55.08	5.15 %	$ 4.95 B	Schweiz
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.7	3.66 %	$ 452 M	Britain
Galapagos NV GLPG	1.03 M	$ 28.81	1.48 %	$ 2.69 B	Belgium